Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study

被引：0
|
作者：
Yu, Evan [1 ]
Park, Se Hoon [2 ]
Huang, Yi-Hsiu [3 ]
Bennamoun, Mostefa [4 ]
Xu, Lu [5 ]
Kim, Jeri [5 ]
Antonarakis, Emmanuel [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Inst Mutualiste Montsouris, Paris, France
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P390
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
    Morris, Michael J.
    Heller, Glenn
    Hillman, David W.
    Bobek, Olivia
    Ryan, Charles
    Antonarakis, Emmanuel S.
    Bryce, Alan H.
    Hahn, Olwen
    Beltran, Himisha
    Armstrong, Andrew J.
    Schwartz, Lawrence
    Lewis, Lionel D.
    Beumer, Jan H.
    Langevin, Brooke
    McGary, Eric C.
    Mehan, Paul T.
    Goldkorn, Amir
    Roth, Bruce J.
    Xiao, Han
    Watt, Colleen
    Taplin, Mary-Ellen
    Halabi, Susan
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3352 - +
  • [22] Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
    Freedland, Stephen J.
    Li, Sophia
    Pilon, Dominic
    Bhak, Rachel H.
    Narkhede, Sahil
    Lefebvre, Patrick
    Young-Xu, Yinong
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 635 - 642
  • [23] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [25] Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.
    Lopez-Campos, Fernando
    Gomez-Iturriaga, Alfonso
    Llacer Perez, Casilda
    Henriquez, Ivan
    Peleteiro, Paula
    Lozano, Rebeca
    Castano, Ana
    Romero-Laorden, Nuria
    Molina-Cerrillo, Javier
    Alvarez-Rodriguez, Sara
    Piquer, Teresa
    Navarro-Castellon, Joaquin
    Jose Conde-Moreno, Antonio
    Ramirez-Backhaus, Miguel
    Barrionuevo, Patricia
    Garcia, Raquel
    de los Llanos Perez-Haro, Maria
    Castro, Elena
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] PHARMACOECONOMIC ANALYSIS OF ENZALUTAMIDE AND ABIRATERONE FOR TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Avxentyev, N. A.
    Frolov, M.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [27] Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    de Bono, Johann
    Sweeney, Christopher
    Chi, Kim N.
    Olmos, David
    Sandhu, Shahneen
    Massard, Christophe
    Garcia, Josep
    Chen, Geng
    Harris, Adam
    Schenkel, Fanny
    Sane, Rucha
    Hinton, Healther
    Bracarda, Sergio
    Sternberg, Cora N.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 230 - +
  • [28] Economic Outcomes in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Huang, Ahong
    Schultz, Neil M.
    Sandin, Rickard
    Wang, Li
    Baser, Onur
    George, Daniel J.
    ADVANCES IN THERAPY, 2020, 37 (05) : 2083 - 2097
  • [29] BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
    Hussain, Maha H. A.
    Kocherginsky, Masha
    Agarwal, Neeraj
    Zhang, Jingsong
    Adra, Nabil
    Paller, Channing Judith
    Picus, Joel
    Reichert, Zachery R.
    Szmulewitz, Russell Zelig
    Tagawa, Scott T.
    Whang, Young E.
    Dreicer, Robert
    Kuzel, Timothy
    Bazzi, Latifa
    Gerke, Travis A.
    Daignault-Newton, Stephanie
    Chinnaiyan, Arul
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
    Castro, Elena
    Wang, Di
    Walsh, Sarah
    Craigie, Samantha
    Haltner, Anja
    Nazari, Jonathan
    Niyazov, Alexander
    Samjoo, Imtiaz A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
12345